Survey of Ophthalmology
Volume 50, Issue 4 , Pages 297-350 , July 2005

Current Concepts in the Etiology and Treatment of Behçet Disease

  • Cem Evereklioglu, MD

      Affiliations

    • Corresponding Author InformationReprint address: Dr. Cem Evereklioglu, Sivas Cad. Cebeci Apt. A-Blok. 175/15, TR-38020, Kayseri, Turkey.

References 

  1. Abadog˘lu O, Osma E, Uçan ES, et al. Behçet's disease with pulmonary involvement, superior vena cava syndrome, chyloptysis and chylous ascites. Respir Med. 1996;90:429–431
  2. Accardo-Palumbo A, Triolo G, Carbone MC, et al. Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. Clin Exp Rheumatol. 2000;18:495–498
  3. Acican T, Gürkan OU. Azathiopine-steroid combination therapy for pulmonary arterial aneurysms in Behçet's disease. Rheumatol Int. 2001;20:171–174
  4. Adam B, Çalikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol. 2004;18:318–320
  5. Ahmad T, Neville M, Marshall SE, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet. 2003;12:647–656
  6. Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?. Arthritis Rheum. 2003;48:807–813
  7. Ak E, Harputluoglu U, Oghan F, Baykal B. Behçet's disease and hearing loss. Auris Nasus Larynx. 2004;31:29–33
  8. Akdeniz N, Eşrefoglu M, Keleş MS, et al. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease. Ann Acad Med Singapore. 2004;33:596–599
  9. Akman-Demir G, Bahar S, Çoban O, et al. Cranial MRI in Behçet's disease: 134 examinations of 98 patients. Neuroradiology. 2003;45:851–859
  10. Akman-Demir G, Serdaroglu P, Taşçi B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999;122:2171–2182
  11. Akpolat T, Akkoyunlu M, Akpolat I, et al. Renal Behçet's disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31:317–337
  12. Akpolat T, Diri B, Oguz Y, et al. Behçet's disease and renal failure. Nephrol Dial Transplant. 2003;18:888–891
  13. Aksu K, Kabasakal Y, Sayiner A, et al. Prevalences of hepatitis A, B, C and E viruses in Behçet's disease. Rheumatology (Oxford). 1999;38:1279–1281
  14. Aksu K, Turgan N, Oksel F, et al. Hyperhomocysteinaemia in Behçet's disease. Rheumatology (Oxford). 2001;40:687–690
  15. Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behçet's disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry. 2003;74:608–613
  16. Al-Fahad SA, Al-Araji AH. Neuro-Behçet's disease in Iraq: a study of 40 patients. J Neurol Sci. 1999;170:105–111
  17. Alevizos B, Anagnostara C, Christodoulou GN. Resistant bipolar disorder precipitated by Behçet's syndrome. Bipolar Disord. 2004;6:260–263
  18. Alper G, Yilmaz Y, Ekinci G, Köse O. Cerebral vein thrombosis in Behçet's disease. Pediatr Neurol. 2001;25:332–335
  19. Alpsoy E, Donmez L, Bacanli A, et al. Review of the chronology of clinical manifestations in 60 patients with Behçet's disease. Dermatology. 2003;207:354–356
  20. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467–471
  21. Alpsoy E, Elpek GO, Yilmaz F, et al. Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behçet's disease. Dermatology. 2005;210:31–35
  22. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999;135:529–532
  23. Alpsoy E, Uzun S, Akman A, et al. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet's disease. J Eur Acad Dermatol Venereol. 2003;17:521–524
  24. Altiparmak MR, Tanverdi M, Pamuk ON, et al. Glomerulonephritis in Behçet's disease: report of seven cases and review of the literature. Clin Rheumatol. 2002;21:14–18
  25. Amoura Z, Dodé C, Hue S, et al. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. Arthritis Rheum. 2005;52:608–611
  26. Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol. 1999;43:312–317
  27. Andreu M, Ramanoelina J, Fajnkuchen F, et al. [Treatment of severe Behçet's disease with anti-TNF-α: infliximab. A case report]. Ann Med Interne (Paris). 2002;153:414–415
  28. Arayssi T, Hamra R, Awwad S, et al. Treatment of refractory vitritis in Behçet disease with infliximab. Arthritis Rheum. 2002;46:181
  29. Aridogan BC, Yildirim M, Baysal V, et al. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J Dermatol. 2003;30:602–607
  30. Atalay F, Ernam D, Okten F, Akar N. Elevated FVIII and FIX level in a Behçet's disease patient with intracardiac thrombosis and pulmonary arterial aneurysms. Thromb Res. 2005;115:159–161
  31. Atalay G, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behçet's disease. Clin Exp Rheumatol. 2002;20:S17–20
  32. Ateş A, Aydıntuğ O, Olmez U, et al. Serum homocysteine level is higher in Behcet's disease with vascular involvement. Rheumatol Int. 2005;25:42–44
  33. Atmaca LS, Batioğlu F. The efficacy of cyclosporin A in the treatment of Behçet's disease. Ophthalmic Surg. 1994;25:321–327
  34. Atmaca LS, Batioğlu F, Idil A. Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1996;234:94–99
  35. Atmaca LS, Sonmez PA. Fluorescein and indocyanine green angiography findings in Behçet's disease. Br J Ophthalmol. 2003;87:1466–1468
  36. Avci O, Ellidokuz E, Simşek I, et al. Helicobacter pylori and Behçet's disease. Dermatology. 1999;199:140–143
  37. Avunduk MC, Avunduk AM, Oztekin E, et al. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res. 2004;79:357–365
  38. Aygündüz M, Bavbek N, Öztürk M, et al. Serum beta 2-microglobulin reflects disease activity in Behçet's disease. Rheumatol Int. 2002;22:5–8
  39. Aykutlu E, Baykan B, Serdaroglu P, et al. Epileptic seizures in Behçet disease. Epilepsia. 2002;43:832–835
  40. Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803–806
  41. Azizlerli G, Sarica R, Köse A, et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology. 1996;192:239–241
  42. Bang D, Chun YS, Haam IB, et al. The influence of pregnancy on Behçet's disease. Yonsei Med J. 1997;38:437–443
  43. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53–58
  44. Barnes CG, Yazici H. Behçet's syndrome. Rheumatology (Oxford). 1999;38:1171–1174
  45. Batioğlu F, Atmaca LS, Karabulut HG, Beyza Sayin D. Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet disease. Acta Ophthalmol Scand. 2003;81:283–285
  46. Bautista-Hernandez V, Gutierrez F, Capel A, et al. Endovascular repair of concomitant celiac trunk and abdominal aortic aneurysms in a patient with Behçet's disease. J Endovasc Ther. 2004;11:222–225
  47. Bayazit YA, Evereklioğlu C, Ozer E, et al. Neurotological status in Behçet's disease and its ophthalmological correlates. Postgrad Med J. 2004;80:724–728
  48. Bayraktar Y, Özaslan E, Van Thiel DH. Gastrointestinal manifestations of Behçet's disease. J Clin Gastroenterol. 2000;30:144–154
  49. Baysal T, Özişik HI, Karlidag R, et al. Proton MRS in Behçet's disease with and without neurological findings. Neuroradiology. 2003;45:860–864
  50. Behçet H. Uber rezidivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157
  51. Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum. 2004;50:2291–2295
  52. BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986;70:589–592
  53. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988;20:136–143
  54. BenEzra D, Maftzir G, Barak V. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behçet disease. Am J Ophthalmol. 1997;123:593–598
  55. Benitez-De-Castillo JM, Martinez-De-La-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab). Eye. 2004;(E Pub) in press doi:10.1038/sj.eye.6701689
  56. Birol A, Ulkatan S, Kocak M, Erkek E. Peripheral neuropathy in Behçet's disease. J Dermatol. 2004;31:455–459
  57. Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's disease. J Rheumatol. 2001;28:1283–1287
  58. Borlu M, Ukşal Ü, Ferahbaş A, Evereklioglu C: Clinical features of Behçet's disease in children. Int J Dermatol (in press)
  59. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999;41:773–780
  60. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb. 2004;33:375–381
  61. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001;46:209–233
  62. Brik R, Shamali H, Bergman R. Successful thalidomide treatment of severe infantile Behçet's disease. Pediatr Dermatol. 2001;18:143–145
  63. Buckley CH, Hadoke PW, O'Brien CJ. Role of the endothelium in modulating functional responses of isolated bovine anterior ciliary arteries to vasoconstrictor agonists. Br J Ophthalmol. 1998;82:826–829
  64. Bükülmez G, Akan T, Ciliv G. Serum adenosine deaminase levels in patients with psoriasis: a prospective case-control study. EurJ Dermatol. 2000;10:274–276
  65. Caca I, Nazaroglu H, Ünlü K, et al. Color doppler imaging of ocular hemodynamic changes in Behçet's disease. Jpn J Ophthalmol. 2004;48:101–105
  66. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84:154–157
  67. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108:487–495
  68. Cengiz N, Şahin M, Onar M. Correlation of clinical, MRI and Tc-99m HMPAO SPECT findings in neuro-Behçet's disease. Acta Neurol Belg. 2004;104:100–105
  69. Chavis PS, Tabbara KF. Behçet's disease. Int Ophthalmol Clin. 1995;35:43–67
  70. Coşkun M, Bacanli A, Sallakci N, et al. Specific interleukin-1 gene polymorphisms in Turkish patients with Behçet's disease. Exp Dermatol. 2005;14:124–129
  71. Çakir N, Derviş E, Benian O, et al. Prevalence of Behçet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol. 2004;22:53–55
  72. Çalgüneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicilline on mucocutaneous symptoms of Behçet's disease. Dermatology. 1996;192:125–128
  73. Çalgüneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease: a randomized clinical trial. Arthritis Rheum. 1996;39:2062–2065
  74. Çalgüneri M, Onat AM, Öztürk MA, et al. Transverse myelitis in a patient with Behçet's disease: favorable outcome with a combination of interferon-α. Clin Rheumatol. 2005;24:64–66
  75. Çalgüneri M, Öztürk MA, Ertenli I, et al. Effects of interferon-α treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis. 2003;62:492–493
  76. Canataroglu A, Tanriverdi K, Inal T, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease. Rheumatol Int. 2003;23:236–240
  77. Carletto A, Pacor M, Biasi D, et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behçet's disease. J Rheumatol. 1997;24:1332–1336
  78. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol. 2003;42:870–875
  79. Çelet B, Akman-Demir G, Serdaroglu P, et al. Anti-αβ-crystallin immunoreactivity in inflammatory nervous system diseases. J Neurol. 2000;247:935–939
  80. Cemri M, Erkan A, Ozdemir M, Gengel A. Behçet's disease with a large and free right atrial thrombus. Eur J Echocardiogr. 2002;3:233–235
  81. Çetinel B, Akpinar H, Tüfek I, et al. Bladder involvement in Behçet's syndrome. J Urol. 1999;161:52–56
  82. Ceyran H, Akçali Y, Kahraman C. Surgical treatment of vasculo-Behçet's disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa. 2003;32:149–153
  83. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol. 2001;37:517–520
  84. Charteris DG, Champ C, Rosenthal AR, Lightman SL. Behçet's disease: activated T lymphocytes in retinal perivasculitis. Br J Ophthalmol. 1992;76:499–501
  85. Cho M, Hunt TK, Hussain MZ. Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release. Am J Physiol Heart Circ Physiol. 2001;280:2357–2363
  86. Cho YH, Jung J, Lee KH, et al. Clinical features of patients with Behçet's disease and epididymitis. J Urol. 2003;170:1231–1233
  87. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum. 2000;43:692–700
  88. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1–11
  89. Davatchi F, Shahram F, Chams H, et al. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Adv Exp Med Biol. 2003;528:579–584
  90. Davatchi F, Shahram F, Chams H, et al. Methotrexate for ocular lesions of Behçet's disease. Cohort study on 262 patients. Arthritis Rheum. 1998;41:356
  91. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br J Rheumatol. 1988;27:300–302
  92. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. Invest Ophthalmol Vis Sci. 2001;42:3233–3238
  93. de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behçet's disease patients and controls. Invest Ophthalmol Vis Sci. 2000;41:3480–3484
  94. Dé Tran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg. 2001;5:329–335
  95. de Wazieres B, Gil H, Magy N, et al. Treatment of recurrent ulceration with low doses of thalidomide: pilot study in 17 patients. Rev Med Interne. 1999;20:567–570
  96. Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-α production and antigen presentation by Langerhans cells. J Invest Dermatol. 2003;121:1060–1065
  97. Dick AD. Experimental approaches to specific immunotherapies in autoimmune disease. Future treatment of endogenous posterior uveitis?. Br J Ophthalmol. 1995;97:81–88
  98. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996–1002
  99. Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, et al. Oligoclonal T cell expansions in patients with Behçet's disease. Clin Exp Immunol. 1999;117:166–170
  100. Direskeneli H, Ekşioglu-Demiralp E, Yavuz S, et al. T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behçet's disease. J Rheumatol. 2000;27:708–713
  101. Direskeneli H, Keser G, D'Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease. Clin Rheumatol. 1995;14:55–61
  102. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol. 2003;21:44–48
  103. Dönmez A, Aksu K, Çelik HA, et al. Thrombin activatable fibrinolysis inhibitor in Behçet's disease. Thromb Res. 2005;115:287–292
  104. Dündar S, Özcebe I. Behçet's disease and interferon: flaws in research integrity of randomized trial. Lancet. 2000;356:1351
  105. Duygulu F, Evereklioglu C, Çaliş M, et al: Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet's disease; a pilot study. Clin Rheumatol (in press)
  106. Duymaz-Tozkir J, Yilmaz V, Uyar FA, et al. Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet's disease. J Rheumatol. 2005;32:93–97
  107. Düzgün N, Ateş A. Erosive arthritis in a patient with Behçet's disease. Rheumatol Int. 2003;23:265–267
  108. Düzgün N, Ayaşlioglu E, Tutkak H. Serum soluble CD30 levels in Behçet's disease. Clin Exp Rheumatol. 2004;22:17–20
  109. Edres MA, Scully C, Gelbier M. Use of proprietary agents to relieve recurrent aphthous stomatitis. Br Dent J. 1997;182:144–146
  110. Ehrlich GE. Vasculitis in Behçet's disease. Int Rev Immunol. 1997;14:81–88
  111. Ekşioglu-Demiralp E, Direskeneli H, Ergün T, et al. Increased CD4+CD56+ T cell subsets in Behçet's disease. Rheumatol Int. 1999;19:23–26
  112. Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826–832
  113. El Ramahi KM, Al Dalaan A, Al Shaikh A, et al. Renal involvement in Behçet's disease: review of 9 cases. J Rheumatol. 1998;25:2254–2260
  114. Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in Behçet disease. J Glaucoma. 2004;13:441–444
  115. Elidan J, Cohen E, Levi H, BenEzra D. Effect of cyclosporine A on the hearing loss in Behçet's disease. Ann Otol Rhinol Laryngol. 1991;100:464–468
  116. Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin1 and nitric oxide in Behçet's disease. Br J Ophthalmol. 2002;86:653–657
  117. Erdem F, Gündogdu M, Kiki I, et al. Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease. Rheumatol Int, (in press). 2004;15:
  118. Erel A, Özsoy E, Biberoglu G, et al. Serum levels of vitamins A, C, and E, beta-carotene, selenium, and zinc in patients with Behçet's disease: a controlled study. Biol Trace Elem Res. 2003;95:97–106
  119. Ergün T, Ince Ü, Ekşioglu-Demiralp E, et al. HSP 60 expression in mucocutaneous lesions of Behçet's disease. J Am Acad Dermatol. 2001;45:904–909
  120. Erkan F, Çavdar T. Pulmonary vasculitis in Behçet's disease. Am Rev Respir Dis. 1992;146:232–239
  121. Erkan F, Gül A, Tasali E. Pulmonary manifestations of Behçet's disease. Thorax. 2001;56:572–578
  122. Erkan F, Kiyan E, Tunaci A. Pulmonary complications of Behçet's disease. Clin Chest Med. 2002;23:493–503
  123. Erkiliç K, Evereklioglu C, Çekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm. 2003;12:107–116
  124. Ermakova NA. Comparative evaluation of the effectiveness of corticosteroids and cytostatics in treating retinal angiitis in Behçet's disease. Vestn Oftalmol. 2002;118:32–35
  125. Kiraz S, Oztürk MA, Ertenli I, et al. Parvovirus B19 infection in Behçet's disease. Ann Rheum Dis. 2001;60:814–815
  126. Esin S, Gül A, Hodara V, et al. Peripheral blood T cell expansions in patients with Behçet's disease. Clin Exp Immunol. 1997;107:520–527
  127. Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43
  128. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002;41:1213–1214
  129. Evans CA, Jellis J, Hughes SP, et al. Tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis. 1998;177:1582–1587
  130. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother. 2004;5:317–328
  131. Evereklioglu C, Çekmen M, Özkiriş A, et al. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behçet's disease. Mediators Inflamm. 2003;12:255–256
  132. Evereklioglu C, Cokkeser Y, Doganay S, et al. Audio-vestibular evaluation in patients with Behçet's syndrome. J Laryngol Otol. 2001;115:704–708
  133. Evereklioglu C, Er H. Increased corneal thickness in active Behçet's disease. Eur J Ophthalmol. 2002;12:24–29
  134. Evereklioglu C, Er H, Türköz Y, Çekmen M. Serum levels of TNF-a, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002;11:87–93
  135. Evereklioglu C, Inalöz HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. Br J Dermatol. 2002;147:331–336
  136. Evereklioglu C, Ozbek E, Cekmen M, et al. Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behçet's disease: Is it a new urinary activity marker?. Nephrology (Carlton). 2003;8:231–238
  137. Evereklioglu C, Ozbek E, Er H, et al. Urinary adrenomedullin levels are increased and correlated with plasma concentrations in patients with Behçet's syndrome. Int J Urol. 2002;9:296–303
  138. Evereklioglu C, Turkoz Y, Er H, et al. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker?. J Am Acad Dermatol. 2002;46:50–54
  139. Fain O, Mathieu E, Lachassinne E, et al. Neonatal Behçet's disease. Am J Med. 1995;98:310–311
  140. Falappone PC, Iannone F, Scioscia C, et al. The treatment of recurrent uveitis with TNF-α inhibitors. Reumatismo. 2004;56:185–189
  141. Fam AG, Siminovitch KA, Carette S, From L. Neonatal Behçet's syndrome in an infant of a mother with the disease. Ann Rheum Dis. 1981;40:509–512
  142. Farah S, Al-Shubaili A, Montaser A, et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry. 1998;64:382–384
  143. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis. 1996;55:7–20
  144. Feki M, Houman H, Ghannouchi M, et al. Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behçet's disease. Clin Chem Lab Med. 2004;42:1417–1423
  145. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-α 2b for refractory ocular Behçet's disease. Lancet. 1994;343:1428
  146. Fontes V, Machet L, Huttenberger B, et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002;129:1365–1369
  147. Forster DJ. General approach to uveitis patient and treatment strategies. In:  Yanoff M,  Duker JS editor. Ophthalmology. London: Mosby; 1999;p. 1–6
  148. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenic role of interleukin-12. Arthritis Rheum. 1999;42:1967–1974
  149. Fresko I, Yazici H, Bayramiçli M, et al. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet's syndrome. Ann Rheum Dis. 1993;52:619–620
  150. Freysdottir J, Lau S, Fortune F. γ δ T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol. 1999;118:451–457
  151. Fujino Y, Joko S, Masuda K, et al. Cyclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Jpn J Ophthalmol. 1999;43:318–326
  152. Garcia Garcia O, Vidaller Palacin A, Munoz Sanchez J, Roca Linares G. Granulocyte-apheresis in ocular Behçet's disease resistant to medical treatment. Arch Soc Esp Oftalmol. 2004;79:335–340
  153. George RK, Chan CC, Whitcup SM, Nussenblatt RS. Ocular immunopathology of Behçet's disease. Surv Ophthalmol. 1997;42:157–162
  154. Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med. 1998;243:367–372
  155. Ghate JV, Jorizzo JL. Behçet's disease and complex aphthosis. J Am Acad Dermatol. 1999;40:1–18
  156. Giansanti F, Barbera ML, Virgili G, et al. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol. 2004;14:445–448
  157. Göker B, Göker H. Current therapy for Behçet's disease. Am J Ther. 2002;9:465–470
  158. Goldberg I. Ocular inflammatory and steroid-induced glaucoma. In:  Yanoff M,  Duker JS editor. Ophthalmology. London: Mosby; 1999;p. 1–6
  159. Gonzalez-Escribano MF, Rodriguez MR, Aguilar F, et al. Lack of association of MICA transmembrane region polymorphism and Behçet's disease in Spain. Tissue Antigens. 1999;54:278–281
  160. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumor necrosis factor α blocking therapy. Ann Rheum Dis. 2001;60:637
  161. Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J. 2003;79:127–132
  162. Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye. 1998;12:783–788
  163. Grutzkau A, Kruger-Krasagakes S, Baumeister H, et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VGF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell. 1998;9:875–884
  164. Guak TH, Kim YI, Park SM, Jim JS. Paroxysmal focal dystonia in neuro-Behçet by a small ipsilateral thalamic lesion. Eur Neurol. 2002;47:183–184
  165. Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behçet's disease. Thromb Res. 1997;86:197–204
  166. Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19:6–12
  167. Gül A, Aslantaş AB, Tekinay T, et al. Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology. 1999;38:1298–1299
  168. Gül A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22–23. Arthritis Rheum. 2001;44:2693–2696
  169. Gül A, Inanç M, Öcal L, et al. Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis. 2000;59:622–625
  170. Gulli S, Arrigo C, Bocchino L, et al. Remission of Behçet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003;28:19
  171. Gündüz K, Öztürk G, Sözmen EY, et al. Erythrocyte superoxide dismutase, catalase activities and plasma nitrite and nitrate levels in patients with Behçet disease and recurrent aphthous stomatitis. Clin Exp Dermatol. 2004;29:176–179
  172. Günen H, Evereklioglu C, Koşar F, et al. Thoracic involvement in Behçet's disease and its correlation with multiple parameters. Lung. 2000;178:161–170
  173. Gurgey A, Balta G, Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behçet's disease. Blood Coagul Fibrinolysis. 2003;14:121–124
  174. Gürler A, Boyvat A, Tursen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J. 1997;38:423–427
  175. Hama Y, Kaji T, Iwasaki Y, et al. Endovascular management of multiple arterial aneurysms in Behçet's disease. Br J Radiol. 2004;77:615–619
  176. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost. 1991;66:292–294
  177. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med. 2004;117:867–870
  178. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443–450
  179. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon α-2b treatment in Behçet's syndrome. J Rheumatol. 1994;21:1098–1100
  180. Hamuryudan V, Özyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769–774
  181. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary artery aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol. 1994;33:48–51
  182. Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210
  183. Hamzaoui K, Hamzaoui A, Hentati F, et al. Phenotype and functional profile of T cells expressing γδ receptor from patients with active Behçet's disease. J Rheumatol. 1994;21:2301–2306
  184. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Expression of Bcl-2 in inflammatory sites from patients with active Behçet's disease. Mediators Inflamm. 1999;8:101–106
  185. Han SW, Kim GW, Lee J, et al: Successful treatment with stent angioplasty for Budd-Chiari syndrome in Behçet's disease. Rheumatol Int 25:234–7, 2005
  186. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407–413
  187. Harman M, Sayarlioglu M, Arslan H, et al. Fibrosing mediastinitis and thrombosis of superior vena cava associated with Behçet's disease. Eur J Radiol. 2003;48:209–212
  188. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–1892
  189. Hassard PV, Binder SW, Nelson V, Nasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001;120:995–999
  190. Hassikou H, Bono W, Bahiri R, et al. Vascular involvement in Behçet's disease. Two case reports. Jone Bone Spine. 2002;69:416–418
  191. Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behçet's syndrome are not sterile. Ann Rheum Dis. 2004;63:1450–1452
  192. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis. 2004;63:744–745
  193. Hayasaki N, Ito M, Suzuki T, et al. Neutrophilic phlebitis is characteristic of intestinal Behçet's disease and simple ulcer syndrome. Histopathology. 2004;45:377–383
  194. Haznedaroglu E, Karaaslan Y, Büyükaşik Y, et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis. 2000;59:61–63
  195. Haznedaroglu IC, Çelik I, Büyükaşik Y, et al. Haemostasis, thrombosis, and endothelium in Behçet's disease. Acta Haematol. 1998;99:236–237
  196. Haznedaroglu IC, Özcebe O, Çelik I, et al. Haemostatic markers of procoagulant imbalance in Behçet's disease. Eur J Haematol. 1996;57:107–108
  197. Hegab S, Al-Mutawa S. Immunopathogenesis of Behçet's disease. Clin Immunol. 2000;96:174–186
  198. Hemmen T, Perez-Canto A, Distler A, et al. IgA nephropathy in a patient with Behçet's syndrome: case report and review of literature. Br J Rheumatol. 1997;36:696–699
  199. Hewitt J, Escande JP, Lauret P, Perlemuter L. Criteria for diagnosis of Behçet's syndrome. Bull Soc Fr Dermatol Syphiligr. 1969;76:565–568
  200. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin Immunol Immunopathol. 1997;82:12–17
  201. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci. 1998;159:181–185
  202. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behçet's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34:244–246
  203. Hiller N, Lieberman S, Chajek-Shaul T, et al. Thoracic manifestations of Behçet disease at CT. Radiographics. 2004;24:801–808
  204. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol. 1992;62:60–65
  205. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL-6 and interferon-γ by T cells from patients with Behçet's disease. Cell Immunol. 1992;140:410–419
  206. Houman H, Hamzaoui A, Ben Ghorbal I, et al. Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun. 2004;23:267–273
  207. Houman H, Hamzaoui A, Ben Ghorbal I, et al. Tc1/Tc2 ratio in the inflammatory process in patients with Behçet's disease. Mediators Inflamm. 2004;13:247–253
  208. Hu W, Hasan A, Wilson A, et al. Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol. 1998;28:2444–2455
  209. Hughes EH, Dick AD. The pathology and pathogenesis of retinal vasculitis. Neuropathol Appl Neurobiol. 2003;29:325–340
  210. Iannaccone A, Letizia C, Pazzaglia S, et al. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1998;82:498–503
  211. Idil A, Gürler A, Boyvat A, et al. The prevalence of Behçet's disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol. 2002;9:325–331
  212. Ikeda U, Ikeda M, Minota S, Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulation. 1999;99:1230–1235
  213. Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behçet's disease. Clin Exp Immunol. 2005;139:371–378
  214. Inalöz HS, Evereklioglu C, Ünal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome. J Eur Acad Dermatol Venereol. 2004;18:56–61
  215. International Study Group for Behçet's Disease: Criteria for diagnosis of Behçet's disease . Lancet. 1990;335:1078–1080
  216. Iscan ZH, Vural KM, Bayazit M. Compelling nature of arterial manifestations in Behçet disease. J Vasc Surg. 2005;41:53–58
  217. Ishi K, Kawai M, Kikuchi H, et al. Low dose weekly methotrexate therapy for progressive neuro-Behçet's syndrome: a follow up study for 36 months. Arthritis Rheum. 1998;41:233
  218. Ishida S, Shiima C, Edagawa G, et al. Serial MRI findings in a relapsing-remitting form of neuro-Behçet's disease: a case report. Clin Imaging. 2004;28:399–403
  219. Jacyk WK. Behçet's disease in South African blacks: report of five cases. J Am Acad Dermatol. 1994;30:869–873
  220. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449–1453
  221. Kabelitz D, Wesch D, Hinz T. γ δ T cells, their T cell receptor usage and role in human diseases. Springer Semin Immunopathol. 1999;21:55–75
  222. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: an update. Semin Arthritis Rheum. 2001;30:299–312
  223. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's Disease. Semin Arthritis Rheum. 1998;27:197–217
  224. Kaklamani VG, Vaiopoulos G, Markomichelakis N, Kaklamanis P. Recurrent epididymoorchitis in patients with Behçet's disease. J Urol. 2000;163:487–489
  225. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 1997;38:444–454
  226. Kaneko S, Suzuki N, Yamashita N. Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol. 1997;108:204–212
  227. Kanekura T, Gushi A, Iwata M, et al. Treatment of Behçet's disease with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol. 2004;51:83–87
  228. Kanski JJ. Uveitis. Clinical ophthalmology, a systematic approach. London: Butterworth-Heinemann; 2003;pp 271–308
  229. Karaçorlu M, Mudun B, Özdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol. 2004;138:289–291
  230. Karasneh JA, Hajeer AH, Silman A, et al: Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. Rheumatology 44:614–7, 2005
  231. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology. 2001;40:933–938
  232. Karlidag R, Ünal S, Evereklioglu C, et al. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet's disease. J Eur Acad Dermatol Venereol. 2003;17:670–675
  233. Kastner DL. Behçet's disease. In:  Koopman WJ editors. Arthritis and allied conditions. Ohio: Williams & Wilkins; 1997;p. 1291–1297
  234. Katsiari CG, Theodossiadis PG, Kaklamanis PG, et al. Successful long-term treatment of refractory Adamantiades-Behçet's disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol. 2003;528:551–555
  235. Kaya TI, Dur H, Tursen U, Gürler A. Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet's disease. Clin Exp Dermatol. 2002;27:498–501
  236. Keino H, Sakai J, Nishioka K, et al. Clonally accumulating T cells in the anterior chamber of Behçet disease. Am J Ophthalmol. 2000;130:243–245
  237. Kera J, Mizuki N, Ota M, et al. Significant association of HLA-B∗5101 and B∗5108, and lack of association of class II alleles with Behçet's disease in Italian patients. Tissue Antigens. 1999;54:565–571
  238. Kibaroglu A, Ekşioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behçet's disease. Clin Exp Rheumatol. 2004;22:59–63
  239. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain. 1999;122:2183–2194
  240. Kim B, LeBoit PE. Histopathologic features of erythema nodosum-like lesions in Behçet disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol. 2000;22:379–390
  241. Kim CY, Kang SJ, Lee SJ, et al. Opacification of a hydrophilic acrylic intraocular lens with exacerbation of Behçet's uveitis. J Cataract Refract Surg. 2002;28:1276–1278
  242. Kim EH, Mok JW, Bang DS, et al. Intercellular adhesion molecule-1 polymorphism in Korean patients with Behçet's disease. J Korean Med Sci. 2003;18:415–418
  243. Kim HA, Choi KW, Song YW. Arthropathy in Behçet's disease. Scand J Rheumatol. 1997;26:125–129
  244. Kim JU, Chang HK, Lee SS, et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease and rheumatic diseases with vasculitis. Ann Rheum Dis. 2003;62:1083–1087
  245. Kiraz S, Ertenli I, Benekli M, Calgüneri M. Parvovirus B19 infection in Behçet's disease. Clin Exp Rheumatol. 1996;14:71–73
  246. Kiraz S, Ertenli I, Çalgüneri M, et al. Interactions of nitric oxide and superoxide dismutase in Behçet's disease. Clin Exp Rheumatol. 2001;19:25–29
  247. Kiraz S, Ertenli I, Haznedaroglu IC, et al. Pathological haemostasis and “prothrombotic state” in Behçet's disease. Thromb Res. 2002;105:125–133
  248. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996;81:219–223
  249. Kobayashi M, Ito M, Nakagawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology. 2000;36:362–371
  250. Koçer N, Islak C, Siva A, et al. CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015–1024
  251. Koga T, Yano T, Ichikawa Y, et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. Chest. 1993;104:309–311
  252. Kökçam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behçet's disease. Clin Biochem. 2002;35:633–639
  253. Kone-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89–93
  254. Kone-Paut I, Yurdakul S, Bahabri SA, et al. Clinical features of Behçet's disease in children. an international collaborative study of 86 cases. J Pediatr. 1998;132:721–725
  255. Korman U, Cantaşdemir M, Kurugoglu S, et al. Enteroclysis findings of intestinal Behçet's disease: a comparative study with Chron disease. Abdom Imaging. 2003;28:308–312
  256. Köse K, Dogan P, Aşçioglu M, Aşçioglu O. In vitro antioxidant effect of Ginkgo biloba extract (EGb 761) on lipoperoxidation induced by hydrogen peroxide in erythrocytes of Behçet's patients. Jpn J Pharmacol. 1997;75:253–258
  257. Köse K, Yazici C, Asçioglu Ö. The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet's disease. Clin Biochem. 2001;34:125–129
  258. Köse K, Yazici C, Çambay N, et al. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behçet's disease. Tohoku J Exp Med. 2002;197:9–16
  259. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet's disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586–589
  260. Kötter I, Dürk H, Eckstein A, et al. Erosive arthritis and posterior uveitis in Behçet's disease. Treatment with interferon α and interferon γ. Clin Exp Rheumatol. 1996;14:113–115
  261. Kötter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon-α2a: a pilot study. Br J Ophthalmol. 1998;82:488–494
  262. Kötter I, Vonthein R, Muller CA, et al. Behçet's disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol. 2004;31:133–139
  263. Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33:311–319
  264. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431
  265. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003;46:118–121
  266. Kramer M, Ehrlich R, Snir M, et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behçet's disease. Am J Ophthalmol. 2004;138:666–668
  267. Krause I, Monselise Y, Milo G, Weinberger A. Anti-Saccharomyces cerevisiae antibodies—a novel serologic marker for Behçet's disease. Clin Exp Rheumatol. 2002;20:21–24
  268. Krause L. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report. Graefes Arch Clin Exp Ophthalmol. 2003;241:871–874
  269. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine. 2003;82:60–76
  270. Kurhan-Yavuz S, Direskeneli H, Bozkurt N, et al. Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol. 2000;120:162–166
  271. Kuriwaka R, Kunishige M, Nakahira H, et al. Neuro- Behçet's disease with chorea after remission of intestinal Behçet's disease. Clin Rheumatol. 2004;23:364–367
  272. Kurumety U, Okada AA, Usui M, Rao NA. Behçet's syndrome. In:  Yanoff M,  Duker JS editor. Ophthalmology. London: Mosby; 1999;p. 1–4
  273. Kutlay S, Civriz S, Ensari A, et al. Development of amyloidosis in Behçet's syndrome with isolated mucocutaneous involvement. Rheumatol Int. 2004;24:37–39
  274. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet's disease activity index. Rheumatology. 2004;43:73–78
  275. Lazarczyk M, Grzela T, Korczak-Kowalska G, et al. Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep. 2002;9:423–426
  276. Lee KH, Chung HS, Kim HS, et al. Human α-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum. 2003;48:2025–2035
  277. Lee LA. Behçet's disease. Semin Cutan Med Surg. 2001;20:53–57
  278. Lee S, Bang D, Cho YH, et al. Polymerase chain reaction reveals Herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res. 1996;288:179–183
  279. Lee YJ, Kang SW, Yang JI, et al. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res. 2002;106:19–24
  280. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol. 1997;14:21–32
  281. Lehner T, Lavery E, Smith R, et al. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome. Infect Immun. 1991;59:1434–1441
  282. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis. 2004;63:1445–1449
  283. Li B, Yang P, Zhou H, et al. T-bet expression is upregulated in active Behçet's disease. Br J Ophthalmol. 2003;87:1264–1267
  284. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumour necrosis factor α monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis. 2003;62:280–281
  285. Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology. 2003;42:1539–1544
  286. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000;51:207–229
  287. Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology. 2004;111:197–198
  288. Mantaş C, Direskeneli H, Ekşioglu-Demiralp E, Akoğlu T. Serum levels of Th2 cytokines IL-4 and IL-10 in Behçet's disease. J Rheumatol. 1999;26:510–512
  289. Marin ML, Savioli CR, Yamamoto JH, et al. MICA polymorphism in a sample of the Sao Paulo population, Brazil. Eur J Immunogenet. 2004;31:63–71
  290. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650
  291. Marsal S, Falga C, Simeon CP, et al. Behçet's disease and pregnancy relationship study. Br J Rheumatol. 1997;36:234–238
  292. Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol. 2004;18:291–311
  293. Mason RM, Barnes CG. Behçet's syndrome with arthritis. Ann Rheum Dis. 1969;28:95–103
  294. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1:1093–1096
  295. Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol. 1999;162:4328–4335
  296. Matsui T, Otsuka M, Maenaka K, et al. Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases. Arthritis Rheum. 2001;44:384–388
  297. Matsuo T, Takahashi M, Inoue Y, et al. Ocular attacks after phacoemulsification and intraocular lens in patients with Behçet disease. Ophthalmologica. 2001;215:179–182
  298. Maytin EV. Heat shock proteins and molecular chaperones: implications for adaptive responses in the skin. J Invest Dermatol. 1995;104:448–455
  299. Mege JL, Dilşen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–1549
  300. Melikoglu M, Altiparmak MR, Fresko I, et al: A reappraisal of amyloidoss in Behçet's syndrome. Rheumatology (Oxford) 40:212–5, 2001
  301. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98–105
  302. Melikoglu M, Özyazgan Y, Fresko I, et al. The response of treatment resistant uveitis in Behçet's syndrome (BS) to a TNF-α blocker, etanercept: an open study. Arthritis Rheum. 2002;46:181
  303. Michelson JB, Chisari FV. Behçet's disease. Surv Ophthalmol. 1982;26:190–203
  304. Mirsattari SM, McGinn GJ, Halliday WC. Neuro-Behçet disease with predominant involvement of the brainstem. Neurology. 2004;27:382–384
  305. Mishima H, Masuda K, Shimada S, et al: Plasminogen activator activity in patients with Behçet's sydrome. Arch Ophthalmol 103:935–6, 1985
  306. Misumi M, Hagiwara E, Tekeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine. 2003;24:210–218
  307. Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Behçet's disease. Int Rev Immunol. 1997;14:33–48
  308. Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet's disease. Proc Natl Acad Sci USA. 1997;94:1298–1303
  309. Mizushima Y. Behçet's disease. Curr Opin Rheumatol. 1991;3:32–35
  310. Mochizuki M. Immunotherapy for Behçet's disease. Intern Rev Immunol. 1997;14:49–66
  311. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763–769
  312. Mochizuki M, Suzuki N, Takeno M, et al. Fine antigen specificity of human γ δ T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol. 1994;24:1536–1543
  313. Mogulkoç N, Burgess MI, Bishop PW. Intracardiac thrombus in Behçet's disease: a systematic review. Chest. 2000;118:479–487
  314. Moises J, Torregrosa JV, Ybarra J, Oppenheimer F. Renal transplantation in a C-ANCA(+) patient with Behçet disease and rapidly progressive glomerulonephritis. Clin Nephrol. 2004;61:357–359
  315. Molet S, Furukawa K, Maghazechi A, et al. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. J Allergy Clin Immunol. 2000;105:333–338
  316. Molinari N, Kone-Paut I, Manna R, et al. Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. Am J Med Genet. 2003;122:115–118
  317. Monastero R, Camarda C, Pipia C, et al. Cognitive impairment in Behçet's disease patients without overt neurological involvement. J Neurol Sci. 2004;220:99–104
  318. Mor F, Weinberger A, Cohen IR. Identification of α-tropomyosin as a target self-antigen in Behçet's syndrome. Eur J Immunol. 2002;32:356–365
  319. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 1993;177:1675–1680
  320. Morelli S, Perrone C, Ferrante L, et al. Cardiac involvement in Behçet's disease. Cardiology. 1997;88:513–517
  321. Morimoto N, Okita Y, Tsuji Y, et al. Inferior mesenteric artery aneurysm in Behçet syndrome. J Vasc Surg. 2003;38:1434–1436
  322. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor α (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol. 2003;528:557–559
  323. Morrissey SP, Miller DH, Hermaszewski R, et al. Magnetic resonance imaging of the central nervous system in Behçet's disease. Eur Neurol. 1993;33:287–293
  324. Moses AG, Dowidar N, Holloway B, et al. Leptin and its relation to weight loss, ob gene expression and the acute-phase response in surgical patients. Br J Surg. 2001;88:588–593
  325. Moshage H. Nitric oxide determinations: Much ado about NO-thing?. Clin Chem. 1997;43:553–556
  326. Mudun BA, Ergen A, Ipçioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm. 2001;9:219–229
  327. Mumcu G, Ergün T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med. 2005;34:13–16
  328. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet. 2001;358:1644
  329. Mussack T, Landauer N, Ladurner R, et al. Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab. Am J Gastroenterol. 2003;98:703–704
  330. Nagafuchi H, Takeno M, Yoshikawa H, et al. Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behçet's disease. Clin Exp Immunol. 2005;139:363–370
  331. Naganuma M, Iwao Y, Kashiwagi K, et al. A case of Behçet's disease accompanied by colitis with longitudinal ulcers and granuloma. J Gastroenterol Hepatol. 2002;17:105–108
  332. Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol. 2004;126:550–556
  333. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22
  334. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-a2a treatment of neuro-Behçet's disease. J Neuroophthalmol. 2001;21:109–111
  335. Nishida T, Mizuki N. Lack of association of interleukin-12 p40 gene (IL12B) polymorphism with Behçet 's disease in the Japanese population. J Dermatol Sci. 2004;34:112–114
  336. Nishiura K, Kotake S, Ichiishi A, Matsuda H. Familial occurrence of Behçet's disease. Jpn J Ophthalmol. 1996;40:255–259
  337. Nishiyama M, Nakae K, Kuriyama T, et al. A study among related pairs of Japanese patients with familial Behçet's disease: group comparisons by interval of disease onsets. J Rheumatol. 2002;29:743–747
  338. Nishiyama M, Nakae K, Umehara T. A study of familial occurrence of Behçet's disease with and without ocular lesions. Jpn J Ophthalmol. 2001;45:313–316
  339. Nomura Y, Kitteringham N, Shiba K, et al. Use of the highly sensitive PCR method to detect the Herpes simplex virus type 1 genome and its expression in samples from Behçet disease patients. J Med Dent Sci. 1998;45:51–58
  340. Noyan T, Şahin I, Şekeroglu MR, Dülger H. The serum vitamin C levels in Behçet's disease. Yonsei Med J. 2003;44:771–778
  341. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol. 1997;14:67–79
  342. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997;123:583–592
  343. Nussenblatt RB, Whitcup SM, de Smet MD, et al. Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann NY Acad Sci. 1996;778:325–337
  344. O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am. 1990;16:423–431
  345. O'Duffy JD, Calamia K, Cohen S, et al. Interferon α treatment of Behçet's disease. J Rheumatol. 1998;25:1938–1944
  346. O'Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behçet's disease. Am J Med. 1976;61:170–178
  347. O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med. 1984;76:75–84
  348. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368
  349. Öktem-Tanor O, Baykan-Kurt B, Gurvit IH, et al. Neuropsychological follow-up of 12 patients with neuro-Behçet disease. J Neurol. 1999;246:113–119
  350. Önder M, Bozkurt M, Gürer MA, Gülekon A. Natural cellular cytotoxicity in Behçet's disease. J Dermatol. 1994;21:239–243
  351. Önder M, Gürer MA. Behçet's disease: an enigmatic vasculitis. Clin Dermatol. 1999;17:571–576
  352. Önder M, Gürer MA. The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol. 2000;15:126–136
  353. Örem A, Cimşit G, Deger O, et al. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease. Dermatology. 1999;198:243–246
  354. Örem A, Efe H, Deger O, et al. Relationship between lipid peroxidation and disease activity in patients with Behçet's disease. J Dermatol Sci. 1997;16:11–16
  355. Örem A, Vanizor B, Cimşit G, et al. Decreased nitric oxide production in patients with Behçet's disease. Dermatology. 1999;198:33–36
  356. Osborne NN, Barnett NL, Herrera AJ. NADPH diaphorase localization and nitric oxide synthase activity in the retina and anterior uvea of the rabbit eye. Brain Res. 1993;610:194–198
  357. Ota M, Mizuki N, Katsuyama Y, et al. The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet. 1999;64:1406–1410
  358. Özatli D, Sayinalp N, Büyükaşik Y, et al. Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state. Rheumatol Int. 2002;21:137–140
  359. Özdemir R, Barutçu I, Sezgin AT, et al. Vascular endothelial function and plasma homocysteine levels in Behçet's disease. Am J Cardiol. 2004;94:522–525
  360. Özen S. Vasculopathy, Behçet's syndrome, and familial Mediterranean fever. Curr Opin Rheumatol. 1999;11:393–398
  361. Özge C, Çalikoglu M, Yildiz A, et al. Bilateral pulmonary artery aneurysms with protein C and protein S deficiency in a patient with Behçet's disease. Scand J Rheumatol. 2004;33:52–54
  362. Öztaş MO, Önder M, Gürer MA, et al. Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behçet's disease. Clin Exp Dermatol. 2005;30:61–63
  363. Öztürk MA, Ertenli I, Kiraz S, et al. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. Rheumatol Int. 2004;24:98–102
  364. Öztürk MA, Özbalkan Z, Onat AM, et al. Decreased protein Z concentrations complicating the hypercoagulable state of Behçet's disease. Clin Appl Thromb Hemost. 2003;9:259–263
  365. Özyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241–243
  366. Park JH. Clinical analysis of Behçet disease: arthritic manifestations in Behçet disease may present as seronegative rheumatoid arthritis or palindromic rheumatism. Korean J Intern Med. 1999;14:66–72
  367. Park KS, Ko HJ, Yoon CH, et al. Magnetic resonance imaging and proton magnetic resonance spectroscopy in neuro- Behçet's disease. Clin Exp Rheumatol. 2004;22:561–567
  368. Parks DJ, Cheung MK, Chan CC, Roberge FG. The role of nitric oxide in uveitis. Arch Ophthalmol. 1994;112:544–546
  369. Picco P, Porfirio B, Gattorno M, et al. MICA gene polymorphism in an Italian paediatric series of juvenile Behçet's disease. Int J Mol Med. 2002;10:575–578
  370. Pickering MC, Haskard DO. Behçet's syndrome. J R Coll Physicians Lond. 2000;34:169–177
  371. Pirim I, Atasoy M, Ikbal M, et al. HLA class I and class II genotyping in patients with Behçet's disease: a regional study of eastern part of Turkey. Tissue Antigens. 2004;64:293–297
  372. Polat G, Eskandari G, Kaya TI, et al. Association of the platelet glycoprotein Ia C870T/G873A gene polymorphism and thrombosis in Behçet's patients. Haematologia. 2002;32:121–128
  373. Poon W, Verity DH, Larkin GL, et al. Behçet's disease in patients of west African and Afro-Caribbean origin. Br J Ophthalmol. 2003;87:876–878
  374. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol. 2004;137:850–857
  375. Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol. 2001;46:1–18
  376. Rapelanoro R, Lamarque P, Rousseau L, et al. Epididymitis in Behçet disease. Presse Med. 1997;26:1385
  377. Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998;25:329–333
  378. Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis. Am J Ophthalmol. 1998;125:409–411
  379. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with Infliximab. Rheumatology. 2001;40:473–474
  380. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol. 1995;15:121–129
  381. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease. J Rheumatol. 2004;31:1241–1243
  382. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNF-a blocking treatment. Ann Rheum Dis. 2002;61:283–284
  383. Saba D, Saricaoglu H, Bayram AS, et al. Arterial lesions in Behçet's disease. Vasa. 2003;32:75–81
  384. Saenz A, Ausejo M, Shea B, et al. Pharmacotherapy for Behçet's syndrome (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2004;
  385. Saglam K, Serçe AF, Yilmaz MI, et al. Trace elements and antioxidant enzymes in Behçet's disease. Rheumatol Int. 2002;22:93–96
  386. şahin S, Akoglu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis. 1996;55:128–133
  387. şahin S, Lawrence R, Direskeneli H, et al. Monocyte activity in Behçet's disease. Br J Rheumatol. 1996;35:424–429
  388. şahin I, Noyan T, Karaman E, et al. Mild renal injury in Behçet's disease. Ren Fail. 2004;26:55–57
  389. Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Behçet's disease. Ophthalmology. 1995;102:317–321
  390. Sakane T, Takeno M. Novel approaches to Behçet's disease. Exp Opin Invest Drugs. 2000;9:1993–2005
  391. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341:1284–1291
  392. Salvarani C, Boiardi L, Casali B, et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. J Rheumatol. 2002;29:535–540
  393. Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Behçet's disease. J Rheumatol. 2004;31:1785–1789
  394. Sancak B, Önder M, Öztaş MO, et al. Nitric oxide levels in Behçet's disease. J Eur Acad Dermatol Venereol. 2003;17:7–9
  395. Sanz L, Gonzalez-Escribano MF, de Pablo R, et al. HLA-Cw∗1602: a new susceptibility marker of Behçet's disease in southern Spain. Tissue Antigens. 1998;51:111–114
  396. Saravanan V, Hamilton J. Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin Pharmacother. 2002;3:845–856
  397. Sari RA, Kiziltunç A, Taysy S, et al. Levels of soluble E-selectin in patients with active Behçet's disease. Clin Rheumatol. 2005;24:55–59
  398. Sarwar H, McGrath H, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol. 2005;32:181–183
  399. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003;49:599–600
  400. Scapini P, Lapinet-Vera JA, Gasperini S, et al. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195–203
  401. Scheid P, Bohadana A, Martinet Y. Nicotine patches for aphthous ulcers due to Behçet's syndrome. New Engl J Med. 2000;343:1816–1817
  402. Scheinfeld N. Off-label uses and side effects of infliximab. J Drugs Dermatol. 2004;3:273–284
  403. Schirmer M, Calamia KT, O'Duffy JD. Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease?. J Rheumatol. 1999;26:2511–2512
  404. Seder RA, Le Gros GG. The functional role of CD8+ T helper type 2 cells. J Exp Med. 1995;181:5–7
  405. Seider N, Beiran I, Scharf J, Miller B. Intravenous immuno globulin therapy for resistant ocular Behçet's disease. Br J Ophthalmol. 2001;85:1287–1288
  406. Şengül N, Demirer S, Yerdel MA, et al. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. World J Surg. 2001;24:1584–1588
  407. Şentürk MU, şentürk UK, Başak PY, et al. Serum and skin nitrite levels in patients with Behçet's disease. J Eur Acad Dermatol Venereol. 2003;17:614–615
  408. Şentürk T, Aydintug O, Kuzu I, et al. Adhesion molecule expression in erythema nodosum-like lesions in Behçet's disease. A histopathological and immunohistochemical study. Rheumatol Int. 1998;18:51–57
  409. Serdaroglu P. Behçet's disease and the nervous system. J Neurol. 1998;245:197–205
  410. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61:51–53
  411. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–406
  412. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295–296
  413. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross- over study. J Dermatol. 2002;29:267–279
  414. Shek LP, Lee YS, Lee BW, Lehman TS. Thalidomide responsiveness in an infant with Behçet's syndrome. Pediatrics. 1999;103:1295–1297
  415. Shek LP, Lim DL. Thalidomide in Behçet's disease. Biomed Pharmacother. 2002;56:31–35
  416. Shenoy R. Conjunctival ulcer: mucocutaneous or ocular manifestation of Behçet's disease? A case report. Eur J Ophthalmol. 2002;12:435–436
  417. Sheu SJ, Yang CA. Macular hole in Behçet's disease. Kaohsiung J Med Sci. 2004;20:558–562
  418. Shimizu T. Behçet's disease. Jpn J Ophthalmol. 1974;18:291–294
  419. Şimşek H, Dündar S, Telatar H. Treatment of Behçet's disease with indomethacin. Int J Dermatol. 1991;30:54–57
  420. Siva A, Altintaş A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347–357
  421. Siva A, Kantarci OH, Saip S, et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248:95–103
  422. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723–728
  423. Sohn S, Lee ES, Bang D, Lee S. Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol. 1998;8:21–23
  424. Sönmezoglu M, Derviş E, Badur S, Yenen OS. Examination of the relationship between the hepatitis C virus and Behçet's disease. J Dermatol. 2004;31:442–443
  425. Sonoda KH, Enaida H, Ueno A, et al. Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol. 2003;87:1010–1014
  426. Sonoda KH, Inaba S, Ariyama A, et al. Therapeutic neutrophil apheresis in patients with ocular Behçet disease. Arch Ophthalmol. 2005;123:267–269
  427. Soy M, Erken E, Konca K, Özbek S. Smoking and Behçet's disease. Clin Rheumatol. 2000;19:508–509
  428. Soylu M, Demircan N, Pelit A. Pars plana vitrectomy in ocular Behçet's disease. Int Ophthalmol. 2001;24:219–223
  429. Spalton DJ. Intraocular inflammation. In:  Spalton DJ,  Hitchings RA,  Hunter PA editor. Atlas of clinical ophthalmology. London: Mosby; 1994;p. 1–32
  430. Stanford MR, Kasp E, Whiston R, et al. Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats. Clin Exp Immunol. 1994;97:226–231
  431. Stark AC, Bhakta B, Chamberlain MA, et al. Life-threatening transient neonatal Behçet's disease. Br J Rheumatol. 1997;36:700–702
  432. Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2 and interferon-γ-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci. 1998;39:996–1004
  433. Süllü Y, Öge I, Erkan D, et al. Cyclosporine-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand. 1998;76:96–99
  434. Süllü Y, Şentürk N, Yildiz L, et al. Bcl-2 expression in skin pathergy reaction of Behçet's disease. Dermatology. 2001;202:90–93
  435. Suzuki N, Kaneko S, Ichino M, et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. Arthritis Rheum. 1997;40:1157–1167
  436. Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:1311–1321
  437. Takeno M, Kariyone A, Yamashita N, et al. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum. 1995;38:426–433
  438. Tanaka T, Suzuki J, Yamakawa N, Usui M. Molecular biological analysis of retinal and streptococcal heat-shock protein 60. Jpn J Ophthalmol. 2000;44:692
  439. Tanaka T, Yamakawa N, Koike N, et al. Behçet's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm. 1999;7:69–74
  440. Tanaka T, Yamakawa N, Yamaguchi H, et al. Common antigenicity between Yersinia enterocolitica-derived heat-shock protein and the retina, and its role in uveitis. Ophthalmic Res. 1996;28:284–288
  441. Tanriverdi N, Taşkintuna I, Duru C, et al. Health-related quality of life in Behçet patients with ocular involvement. Jpn J Ophthalmol. 2003;47:85–92
  442. Taşçi B, Direskeneli H, Serdaroglu P, et al. Humoral immune response to mycobacterial heat shock protein (HSP) 65 in the cerebrospinal fluid of neuro-Behçet patients. Clin Exp Immunol. 1998;113:100–104
  443. Tataroglu C, Tursen U, Ünal O, Kaya TI. Long-latency reflexes in patients with Behçet's disease. J Neurol Sci. 2004;220:67–71
  444. Tekeli O, Özdemir O. Heidelberg retina tomograph in ocular Behçet's disease. Eye. 2004;18:143–146
  445. The Behçet's Disease Research Committee of Japan . skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease: a multicenter study. J Rheumatol. 1989;16:506–511
  446. Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Exp Opin Invest Drug. 2001;10:1279–1289
  447. Thurau SR, Diedrichs-Mohring M, Fricke H, et al. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett. 1999;68:205–212
  448. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143:718–726
  449. Toda K, Shiratori Y, Yasuda M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet's disease. J Gastroenterol. 2002;37:844–848
  450. Tohme A, Aoun N, El-Rassi B, Ghayad E. Vascular manifestations of Behçet's disease. Eighteen cases among 140 patients. Joint Bone Spine. 2003;70:384–389
  451. Tohme A, Haddad F, Ghayad E. Neurologic manifestations in Behçet's disease. 16 cases in a cohort of 110 patients. Ann Med Intern. 1997;148:118–124
  452. Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology. 2001;40:192–195
  453. Toker E, Kazokoglu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002;86:521–523
  454. Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet's syndrome with chimeric tumor necrosis factor α antibody. Gut. 2001;49:725–728
  455. Triolo G, Accardo-Palumbo A, Triolo G, et al. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330–337
  456. Triolo G, Vadalà M, Accardo-Palumbo A, et al. Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis. 2002;61:560–561
  457. Tsui KL, Lee KW, Chan WK, et al. Behçet's aortitis and aortic regurgitation: a report of two cases. J Am Soc Echocardiogr. 2004;17:83–86
  458. Tugal-Tutkun I, Önal S, Altan Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380
  459. Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114–1119
  460. Tunaci M, Özkorkmaz B, Tunaci A, et al. CT findings of pulmonary artery aneurysms during treatment for Behçet's disease. AJR Am J Roentgenol. 1999;172:729–733
  461. Tunç R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Behçet's syndrome. Ann Rheum Dis. 2004;63:1693–1694
  462. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–132
  463. Türköz Y, Evereklioglu C, Mehmet N, et al. Plasma malondialdehyde levels in Behçet's disease with or without ocular involvement. Adv Reprod. 2000;4:31–36
  464. Tursen U, Gürler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. Int J Dermatol. 2003;42:346–351
  465. Tüzün Y, Yurdakul S, Mat CM, et al. Epidemiology of Behçet's syndrome in Turkey. Int J Dermatol. 1996;35:618–620
  466. Uchio E, Matsumoto T, Tanaka SI, et al. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. Clin Exp Rheumatol. 1999;17:179–184
  467. Üstün C. A famous Turkish dermatologist, Dr. Hulusi Behçet. Eur J Dermatol. 2002;12:469–470
  468. Uzun S, Alpsoy E, Durdu M, Akman A. The clinical course of Behçet's disease in pregnancy: a retrospective analysis and review of the literature. J Dermatol. 2003;30:499–502
  469. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54:213–220
  470. Verity DH, Vaughan RW, Kondeatis E, et al. Intercellular adhesion molecule-1 gene polymorphism in Behçet's disease. Eur J Immunogenet. 2000;27:73–76
  471. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol. 1999;128:352–356
  472. Verity DH, Wallace GR, Seed PT, et al. Soluble adhesion molecules in Behçet's disease. Ocul Immunol Inflamm. 1998;6:81–92
  473. Verity DH, Wallace GR, Vaughan RW, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease. Tissue Antigens. 1999;54:264–272
  474. Vikas A, Atul S, Singh R, et al. Behçet's disease with relapsing cutaneous polyarteritis-nodosa-like lesions, responsive to oral cyclosporine therapy. Dermatol Online J. 2003;9:9
  475. Vrabec TR. Exudative retinal detachment in Behçet's disease. Arch Ophthalmol. 2001;119:1383–1386
  476. Webb NJ, Myers CR, Watson CJ, et al. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine. 1998;10:254–257
  477. Wechsler B, Du LT, Kieffer E. Cardiovascular manifestations of Behçet's disease. Ann Med Interne. 1999;150:542–554
  478. Wechsler B, Sable-Fourtassou R, Bodaghi B. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22:14–16
  479. Whincup SM, Csaky KG, Podgor MJ, et al. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996;103:1054–1063
  480. Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol. 1994;118:39–45
  481. Wildner G, Thurau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol. 1994;24:2579–2585
  482. Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lepob) mice. J Appl Physiol. 2000;89:2382–2390
  483. Wolf R, Tüzün B, Tüzün Y. Dapsone: unapproved uses or indications. Clin Dermatol. 2000;18:37–53
  484. Xiong M, Elson G, Legarda D, Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol. 1998;153:587–598
  485. Yabuki K, Mizuki N, Ota M, et al. Association of MICA gene and HLA-B∗5101 with Behçet's disease in Greece. Invest Ophthalmol Vis Sci. 1999;40:1921–1926
  486. Yalvaç IS, Sungur G, Turhan E, et al. Trabeculectomy with mitomycin-C in uveitic glaucoma associated with Behçet disease. J Glaucoma. 2004;13:450–453
  487. Yamamoto JH, Minami M, Inaba G, et al. Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. Br J Ophthalmol. 1993;77:584–589
  488. Yamashita N. Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Int Rev Immunol. 1997;14:11–19
  489. Yamashita N, Kaneoka H, Kaneko S, et al. Role of γδ T lymphocytes in the development of Behçet's disease. Clin Exp Immunol. 1997;107:241–247
  490. Yasui K, Ohta K, Kobayashi M, et al. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med. 1996;124:891–893
  491. Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis Rheum. 2004;50:3658–3662
  492. Yato H, Matsumoto Y. CD56+ T cells in the peripheral blood of uveitis patients. Br J Ophthalmol. 1999;83:1386–1388
  493. Yazici C, Köse K, Çaliş M, et al. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?. Br J Dermatol. 2004;151:105–111
  494. Yazici H, Başaran G, Hamuryudan V, et al. The ten-year mortality in Behçet's syndrome. Br J Rheumatol. 1996;35:139–141
  495. Yazici H. Behçet's syndrome: where do we stand?. Am J Med. 2002;112:75–76
  496. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs. 1991;42:796–804
  497. Yazici H, Chamberlain MA, Tüzün Y, et al. A comparative study of the pathergy reaction among Turkish and British patients with Behçet's disease. Ann Rheum Dis. 1984;43:74–75
  498. Yazici H, Özyazgan Y. Medical management of Behçet's syndrome. Dev Ophthalmol. 1999;31:118–131
  499. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. New Engl J Med. 1990;322:281–285
  500. Yazici H, Yurdakul S, Hamuryudan V. Behçet disease. Curr Opin Rheumatol. 2001;13:18–22
  501. Yeşilova Z, Pay S, Öktenli C, et al: Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy? Rheumatol Int (in press)
  502. Yilmaz G, Sizmaz S, Yilmaz ED, et al. Aqueous humor nitric oxide levels in patients with Behçet disease. Retina. 2002;22:330–335
  503. Yoshida A, Kawashima H, Motoyama Y, et al. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology. 2004;111:810–815
  504. Yoshida S, Fujimori K, Hareyama M, Nakata T. Cardiac thrombus in Behçet disease. Chest. 2001;120:688–689
  505. Yoshida T, Tanaka M, Sotomatsu A, et al. Serum of Behçet's disease enhances superoxide production of normal neutrophils. Free Radic Res. 1998;28:39–44
  506. Yu HG, Lee DS, Seo JM, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis. Clin Exp Immunol. 2004;137:437–443
  507. Yücel AE, Kart-Köseoglu H, Akova YA, et al. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology. 2004;43:394–396
  508. Yurdakul S, Günaydin I, Tüzün Y, et al. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15:820–822
  509. Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin Rheumatol. 2004;16:38–42
  510. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44:2686–2692
  511. Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Behçet's disease. Ophthalmology. 2003;110:1137–1141
  512. Zouboulis CC, Kötter I, Djawari D, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J. 1997;38:411–422
  513. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon-α. Arch Dermatol. 1998;134:1010–1016
  514. Zumbach MS, Boehme MW, Wahl P, et al. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab. 1997;82:4080–4082
  515. Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol. 1999;60:323–330

 The author reported no proprietary or commerical interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(05)00050-0

doi: 10.1016/j.survophthal.2005.04.009

Survey of Ophthalmology
Volume 50, Issue 4 , Pages 297-350 , July 2005

Article Tools

* Image Usage & Resolution